Glenmark gets USFDA nod for generic Clindamycin phosphate gel

Glenmark gets USFDA nod for generic Clindamycin phosphate gel

88
USFDA
Picture: Pixabay

Last Updated on February 12, 2021 by The Health Master

Glenmark Pharmaceuticals Limited has received final approval from United States Food & Drug Administration (USFDA) for clindamycin phosphate gel USP, 1%, the generic version of Cleocin T gel, 1%, of Pharmacia & Upjohn.

According to IQVIA sales data for the 12 month period ending December 2020, the Cleocin T gel, 1% market achieved annual sales of approximately $73.8 million.

Glenmark’s current portfolio consists of 169 products authorized for distribution in the US marketplace and 42 ANDA’s pending approval with the USFDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Also read:

Lupin gets US FDA nod to market generic Tavaborole topical solution

Alembic Pharma gets 5 observations from USFDA


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading